Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT-AF
NCT06722196Phase 3
Key facts
- Status
- Recruiting
- Start
- Feb 2025
- Primary completion
- Jan 2027
- Countries
- 1
- Sponsor
- Jilin Heart Hospital
- Modality
- Small Molecules
- Drugs
- amiodarone
- Conditions
- Atrial fibrillation (AFib)
01
Overview
Phase 3, randomised, double-blind trial of amiodarone in Atrial fibrillation (AFib) (2 arms), sponsored by Jilin Heart Hospital. Primary endpoint: Postoperative Atrial Fibrillation at 5 days. Started Feb 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Experimental
2 patches soaked in cordarone hydrochloride (150 mg/3 ml each)
Sham
2 patches soaked in saline solution (3 ml each)
03
Who it enrols
Patients scheduled for elective cardiac surgery through complete sternotomy without a history of arrhythmias, thyroid dysfunction, or implanted cardiac devices.
04
Endpoints
Primary
Postoperative Atrial Fibrillation
Beyond the preview
Go deeper on NCT06722196.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722196.